Cargando…
Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population
BACKGROUND: To investigate the predictive value of chemokine CCL27 for identifying early stage nasopharyngeal carcinoma (NPC) patients within a population seropositive for Epstein-Barr virus (EBV) capsid antigen-specific IgA (VCA-IgA). METHODS: CCL27 in plasma samples from 104 NPC patients, 112 VCA-...
Autores principales: | Mao, Min-jie, Xue, Ning, Wang, Xue-ping, Chi, Pei-dong, Liu, Yi-jun, Huang, Qi, Dai, Shu-qin, Liu, Wan-li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751682/ https://www.ncbi.nlm.nih.gov/pubmed/29295705 http://dx.doi.org/10.1186/s12885-017-3718-2 |
Ejemplares similares
-
IgA antibodies to Epstein-Barr viral capsid antigens in saliva of nasopharyngeal carcinoma patients.
por: Ho, H. C., et al.
Publicado: (1977) -
Factors affecting serum IgA antibody to Epstein-Barr viral capsid antigens in nasopharyngeal carcinoma.
por: Ho, H. C., et al.
Publicado: (1978) -
Plasma Macrophage Migration Inhibitory Factor and CCL3 as Potential Biomarkers for Distinguishing Patients with Nasopharyngeal Carcinoma from High-Risk Individuals Who Have Positive Epstein-Barr Virus Capsid Antigen-Specific IgA
por: Xue, Ning, et al.
Publicado: (2019) -
Epstein-Barr virus glycoprotein gH/gL antibodies complement IgA-viral capsid antigen for diagnosis of nasopharyngeal carcinoma
por: Li, Rui-Chen, et al.
Publicado: (2016) -
Cigarette smoking increases the risk of nasopharyngeal carcinoma through the elevated level of IgA antibody against Epstein‐Barr virus capsid antigen: A mediation analysis
por: Hsu, Wan‐Lun, et al.
Publicado: (2020)